Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS · NASDAQ Global Select
-$0.02 today
Vol 0.12M · Avg 0.10M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
18.8%
avg 15.0%
ROIC
46.0%
avg -56.1%
ROA
-22.5%
avg -43.1%
Analysis
ROIC is currently the strongest return metric at 46.0% versus its period average of -56.1%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Fenglin Hsu | Chief Technology Officer & Director | — | — | 77 | — | — |
Fu-Feng Kuo | Chief Executive Officer & Chairwoman of the Board | — | — | 68 | — | — |
Wanwen Su | Chief Science Officer | — | — | 51 | — | — |
Wei Zhang | Chief Financial Officer | — | — | 45 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.19B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.58B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.34B
Legend Biotech Corporation
NASDAQ:LEGN
$5.14B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.06B
Celcuity Inc.
NASDAQ:CELC
$4.26B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.22B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.19B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.73B
Ascentage Pharma Group International
NASDAQ:AAPG
$404.16M
Who manages MENS?
Jyong Biotech Ltd. Ordinary Shares (MENS) lists 4 active executives. The top listed executive is Fenglin Hsu, Chief Technology Officer & Director.
Explore More
Continue the stock analysis
Jump to another research area for this company.